BerryGenomics
Company: Beijing BerryGenomics Biotechnology Co., Ltd.
Legal representative: Gao Yang
Phone: 01053259188
Brand birthplace: Beijing
Brand creation time: 2010-05-18
Main Products: Medical Devices
BerryGenomics
Beijing BerryGenomics Biotechnology Co., Ltd. was established in May 2010. It is a research and development biotechnology company that focuses on applying high-throughput gene sequencing technology and providing overall solutions for clinical medical disease screening and diagnosis.
With the promotion of biomedicine as a “national strategic emerging industry”, Berry Gene relies on the core technology independently developed to practice human genome sequencing technology in clinical testing. In the field of screening and diagnosis of congenital genetic diseases, Berry Gene has developed Bebian’s “DNA prenatal testing” technology (abbreviated as Bebian) with a full set of independent intellectual property rights, realizing prenatal testing of fetal chromosomal diseases. Subsequently, it can be used for the Konoan chromosomal disease detection (referred to as Konoan) for pre-marital pregnancy, prenatal and genetic disease probands, and for the Konoan embryo implantation for the number and structure of abnormal embryos before implantation in assisted reproductive technology. Pre-entry genetic screening (Keyun’an for short) tests have come out one after another, further enriching and improving the testing technology system for genetic disease screening and diagnosis. On this basis, Berry Genomics has successively developed detection technologies for fetal chromosomal microdeletion microduplications and fetal single gene disease genotyping, in order to achieve a safe and full coverage of clinical genetic disease screening and diagnosis.
While continuing to deepen the field of genetic disease screening and diagnosis, Berry Gene successfully launched Onconi tumor molecular diagnostic products based on high-throughput sequencing technology in the field of tumor molecular diagnosis, involving targeted drug testing and efficacy monitoring , Drug monitoring, tumor susceptibility testing, tumor personalized medical testing, to achieve overall coverage of tumor molecular testing. Among them, tumor gene detection with cSMART technology with independent intellectual property rights as the core has opened a clinical model. In addition, the accumulated data of Berry gene in the field of prenatal testing, pre-pregnancy testing, genetic disease testing and tumor testing has been constructed into a large genome database with Chinese population characteristics. Through cooperation with Baylor College of Medicine, Alibaba Cloud and other institutions, Berry Gene will use cloud storage and cloud computing platforms to realize simplified terminal applications and real-time sharing of genomic data.
At this point, Berry gene has formed the technical dimensions of chromosome number and structure level, chromosome microdeletion and microduplication level, and gene level. It gradually covers the product dimensions of pre-marital, pre-pregnancy, pre-natal, newborn, and cancer; from a single individual The interpretation of genomic data to the analysis of population genomic data, and then to the three-dimensional development structure of the digital dimension that guides the interpretation of individual genomic data.